A Drug Discovery Scientist is central to the early stages of developing new therapeutic agents that target specific diseases. Their work begins by identifying promising biological targets—such as proteins, enzymes, or genes—linked to a disease pathway. Once a target is validated, these scientists screen libraries of chemical or biological compounds to find those with the potential to interact effectively and selectively. Advanced tools like high-throughput screening, molecular modeling, and bioinformatics assist in narrowing down viable candidates. The selected hits are then optimized through medicinal chemistry to improve their efficacy, selectivity, and safety profiles. This foundational research sets the stage for transforming a compound into a potential drug candidate.
Collaboration is essential in this role, as Drug Discovery Scientists work closely with biologists, chemists, toxicologists, and data analysts to evaluate how compounds behave in biological systems. They study pharmacodynamics, pharmacokinetics, and toxicity profiles to ensure that a candidate is not only active but also safe for progression. This position demands a strong understanding of disease mechanisms, structure-activity relationships, and the latest scientific technologies. With the growing influence of AI and machine learning, the field is becoming increasingly data-driven, enhancing precision and speed in discovering new therapies. Ultimately, their efforts help bridge the gap between theoretical research and the development of life-changing treatments.
Title : Medical liver biopsy: Toward a personalized approach
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Emerging formulation and delivery applications of vitamin E TPGS
Andreas M Papas, Antares Health Products, United States
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through design-inspired biotech- & biopharma-driven applications and upgraded business marketing to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Mathematical modeling the disc diffusion test: Antibacterial activity of copper-doped SnO2
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Genetic keys and nano locks: Unlocking personalized medicine
Srividya Narayanan, Northeastern University, United States
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico